ArticleInternational journal of environmental research and public health2022
Ultra-High Frequency Distortion Product Otoacoustic Emissions for Detection of Hearing Loss and Tinnitus.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.Scientific reports · 2026Article
- Tinnitus in Normal-Hearing Individuals: Is Outer Hair Cell Dysfunction the Mechanism?Journal of clinical medicine · 2025Article
- Audiological Methods for Early Detection of Hearing Loss in Healthcare Worker.Healthcare (Basel, Switzerland) · 2025Article
- Comparisons of Audiologic Characteristics in Patients with Continuous and Intermittent Tinnitus.Clinics and practice · 2024Article
- ChatGPT for Tinnitus Information and Support: Response Accuracy and Retest after Three and Six Months.Brain sciences · 2024Article
- Effect of the COVID-19 Pandemic on Resting-State Brain Activity in Individuals with Tinnitus.Brain sciences · 2024Article
- Cooling the Cochlea: Slowing Down Metabolism May Be a Way of Protecting Hearing from Surgical Trauma.Medicina (Kaunas, Lithuania) · 2023Review
- Otoacoustic emissions value in patients with idiopathic sudden sensorineural hearing loss.Journal of otology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have suggested that distortion product otoacoustic emissions (DPOAEs) may be an early marker not only of hearing loss (HL) but also of tinnitus. The purpose of this study was to investigate whether DPOAEs measured up to 16 kHz are affected by the presence of tinnitus. Pure tone thresholds and DPOAEs were measured in two groups: 55 patients with tinnitus and 63 subjects without tinnitus. The subjects were divided into three groups according to their audiometric results-better than 25 dB HL at all tested frequencies from 0.125 to 16 kHz, better than 25 dB up to 8 kHz, and hearing impaired. Receiver operator characteristics (ROCs) were used to test whether DPOAEs could differentiate between normal hearing, hearing loss, and tinnitus. Comparison of tinnitus subjects with the control group, matched accurately according to thresholds, did not yield any significant difference in DPOAEs. However, in both these groups hearing loss was accompanied by a decrease in DPOAEs, specifically, at 2-6 kHz and 16 kHz. The results suggest that any decrease in DPOAEs seems to be related only to hearing loss and there is no additional effect from tinnitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.